OOIR: Observatory of International Research

Papers

(The median citation count of Diabetes Technology & Therapeutics is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)

Article	Citations
Glycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial	150
The Official Journal of ATTD Advanced Techologies & Treatments for Diabetes CONFERENCE 6–9 MARCH 2024 I FLORENCE & ONLINE	147
New Medications for the Treatment of Diabetes	139
Insulin Delivery Hardware: Pumps and Pens	103
Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5	82
Assessment for Predictors of Rise in Hemoglobin A1c During Extended Use of a Closed-Loop Control System	71
Withdrawal of: Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial (doi: 10.1089/dia.2022.0201)	64
Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Mellitus Patients: Results from the Spanish National Registry	63
Snapshot of CGM Metrics in Adolescents and Adults Achieving Target HbA1c Versus Those Not Meeting Target HbA1c	63
The Health Economics of Automated Insulin Delivery Systems and the Potential Use of Time in Range in Diabetes Modeling: A Narrative Review	54
Mean Glucose and Gestational Weight Gain as Predictors of Large-for-Gestational-Age Infants in Pregnant Women with Type 1 Diabetes Using Continuous Glucose Monitoring	54
The Myth of MARD (Mean Absolute Relative Difference): Limitations of MARD in the Clinical Assessment of Continuous Glucose Monitoring Data	52
Progression from Prediabetes to Diabetes in a Diverse U.S. Population: A Machine Learning Model	50
Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study	47
Variability of Insulin Requirements in Adults with Type 2 Diabetes During Fully Closed-Loop Insulin Delivery	46
The Accuracy of Continuous Glucose Sensors in People with Diabetes Undergoing Hemodialysis (ALPHA Study)	45
Reduced Acute Diabetes Events After FreeStyle Libre System Initiation in People 65 Years or Older with Type 2 Diabetes on Intensive Insulin Therapy in France	44
Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to Policymaking	40
Listening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy	37
MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control	37
The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes	37
Automated Insulin Delivery for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes with Hypoglycemia Unawareness	37
The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes	36
Closed-Loop Insulin Therapy in Older Adults with Type 1 Diabetes: Real-World Data	36
Anticipation of Historical Exercise Patterns by a Novel Artificial Pancreas System Reduces Hypoglycemia During and After Moderate-Intensity Physical Activity in People with Type 1 Diabetes	36

Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study	36
The Type 1 Diabetes and EXercise Initiative: Predicting Hypoglycemia Risk During Exercise for Participants with Type 1 Diabetes Using Repeated Measures Random Forest	35
Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Glycemic Outcomes with Closed-Loop Insulin Delivery	35
Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control	34
Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country	33
Accuracy of the Dexcom G7 Continuous Glucose Monitoring Sensors in People with Diabetes Undergoing Hemodialysis (ALPHA-2 Study)	33
Effect of Interrupting Prolonged Sitting with Frequent Activity Breaks on Postprandial Glycemia and Insulin Sensitivity in Adults with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Thera	33
A Statistical Approach for Assessing the Compliance of Integrated Continuous Glucose Monitoring Systems with Food and Drug Administration Accuracy Requirements	33
New Medications for the Treatment of Diabetes	33
Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE	32
Statistically Adjusting for Wear Time in Randomized Trials of Continuous Glucose Monitors as a Complement to Intent-to-Treat and As-Treated Analyses: Application and Evaluation in Two Trials	31
Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study	31
Personal Glycation Factors and Calculated Hemoglobin A1c for Diabetes Management: Real-World Data from the Diabetes Prospective Follow-up (DPV) Registry	31
Ranting in 2021: Could This Get Any Worse?	29
Does Insulin Delivery Technology Change Our Relationship with Foods? A Scoping Review	29
Immunogenicity of the novel glucagon analog dasiglucagon: Results of a dedicated immunogenicity trial in type 1 diabetes	29
Transatlantic Comparison of Pediatric Continuous Glucose Monitoring Use in the Diabetes-Patienten-Verlaufsdokumentation Initiative and Type 1 Diabetes Exchange Quality Improvement Collaborative	27
Accuracy of a Real-Time Continuous Glucose Monitor in Pediatric Diabetic Ketoacidosis Admissions	27
Adaptive Biobehavioral Control: A Pilot Analysis of Human–Machine Coadaptation in Type 1 Diabetes	27
Sustainable Use of a Real-Time Continuous Glucose Monitoring System from 2018 to 2020	26
Sustained Impact of Intermittently Scanned Continuous Glucose Monitoring on Treatment Satisfaction and Severe Hypoglycemia in Adults with Type 1 Diabetes (FUTURE): An Analysis in People with Normal an	26
Feasibility and Validity of In-Home Self-Collected Capillary Blood Spot Screening for Type 1 Diabetes Risk	26
Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations	26
Weight Gain and Glycemic Control in Adults with Type 1 Diabetes in the T1D Exchange Registry	25
Recurrent Diabetic Ketoacidosis and Extreme Insulin Resistance Due to Anti-Insulin Antibodies: Response to Immunosuppression and Plasma Exchange	25
Endocrine Management and Clinical Outcomes in a Cohort of Pediatric Patients Undergoing Total Pancreatectomy with Islet Autotransplantation	24
Comment on “One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology” by Breton M and Kovatchev B	24
Effects of Macronutrient Intake and Number of Meals on Glycemic Outcomes Over 1 Year in Youth with Type 1 Diabetes	24
Hypoglycemia in Prospective Multicenter Study of Pregnancies with Pre-Existing Type 1 Diabetes on Sensor-Augmented Pump Therapy: The LOIS-P Study	23
Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational Study	23
Virtual Clinics for Diabetes Care	23
Continuous Glucose Monitor Metrics Are Associated with Emergency Department Visits and Hospitalizations for Hypoglycemia and Hyperglycemia, but Have Low Predictive Value	22
Safety and Feasibility of the PEPPER Adaptive Bolus Advisor and Safety System: A Randomized Control Study	22
A Comparison of the Rates of Clock-Based Nocturnal Hypoglycemia and Hypoglycemia While Asleep Among People Living with Diabetes: Findings from the Hypo-METRICS Study	21
Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring Systems	21
Profiles of Intraday Glucose in Type 2 Diabetes and Their Association with Complications: An Analysis of Continuous Glucose Monitoring Data	21
Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality	21
Prevalence, Safety, and Metabolic Control Among Danish Children and Adolescents with Type 1 Diabetes Using Open-Source Automated Insulin Delivery Systems	20
Correction to: Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (doi: 10.1089/dia.2	20
The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference 22‐25 February 2023 I Berlin & Online	20
Technology and Pregnancy	20
Accuracy of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Admitted to Hospital: A Real-World Multicenter Observational Study	20
Comparison of Cgmanalysis, a Free Open-Source Continuous Glucose Monitoring Data Management and Analysis Software, with Commercially Available CGM Platforms: Data Standardization for Diabetes Technolo	19
Decision Support Systems and Closed-Loop	19
High-Throughput Multiplex Electrochemiluminescence Assay Applicable to General Population Screening for Type 1 Diabetes and Celiac Disease	19
New Insulins, Biosimilars, and Insulin Therapy	19
Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections	19
Comment on “Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes” by Messer et al.	19
Removing Barriers, Bridging the Gap, and the Changing Role of the Health Care Professional with Automated Insulin Delivery Systems	18
Evolving Use of Continuous Glucose Monitoring Beyond Intensive Insulin Treatment	18

Impact of Body Composition on the Accuracy of a Medtronic Guardian Continuous Glucose Monitoring System	18
Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study)	18
Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy	17
Disordered Eating Behaviors Among Adolescents and Young Adults with Type 1 Diabetes Treated with Insulin Pumps and Hybrid Closed-Loop Systems	17
Ultrarapid Insulin Use Can Reduce Postprandial Hyperglycemia and Late Hypoglycemia, Even in Delayed Insulin Injections: A Connected Insulin Cap-Based Real-World Study	17
“Fear That One Day I May Not Be Able to Afford Insulin”: The Emotional Burden of Diabetes Costs During Emerging Adulthood	17
Performance of the Dexcom G7 Continuous Glucose Monitoring System in Pregnant Women with Diabetes	17
Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis	16
Population-Based Study on the Implementation of Flash Glucose Monitoring and Severe Hypoglycemia in Adults With Type 1 Diabetes	16
Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes	16
Telemetric Continuous Glucose Monitoring During the COVID-19 Pandemic in Isolated Hospitalized Patients in Denmark: A Randomized Controlled Exploratory Trial	16
Comparison of Insulin Dose Adjustments Made by Artificial Intelligence-Based Decision Support Systems and by Physicians in People with Type 1 Diabetes Using Multiple Daily Injections Therapy	16
Continuous Glucose Monitoring and Recreational Scuba Diving in Type 1 Diabetes: Head-to-Head Comparison Between Free Style Libre 3 and Dexcom G7 Performance	15
Improvement in Mean CGM Glucose in Young People with Type 1 Diabetes During 1 Year of the COVID-19 Pandemic	15
Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Trial	15
Assessing Patterns of Continuous Glucose Monitoring Use and Metrics of Glycemic Control in Type 1 Diabetes and Type 2 Diabetes Patients in the Veterans Health Care System: Integrating Continuous Gluco	15
Challenges of GLP Analog Use for People with Type 1 Diabetes:Issues with Prior Approvals and Tips for Safer Use	15
Is It Time to Replace Time-in-Range with Time-in-Tight-Range? Maybe Not	14
Use of Technology in Older Adults with Type 1 Diabetes: Clinical Characteristics and Glycemic Metrics	14
One-Year Follow-Up of Advanced Hybrid Closed-Loop System in Adults with Type 1 Diabetes Previously Naive to Diabetes Technology: The Effect of Switching to a Calibration-Free Sensor	14
Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study	14
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes	14
Simplified Meal Management in Adults Using an Advanced Hybrid Closed-Loop System	13
Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems	13
Using Digital Health Technology to Prevent and Treat Diabetes	13
Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose	13
Exploring Minimally Invasive Approach to Define Stages of Type 1 Diabetes Remotely	13
Transitioning from Self-Monitoring of Blood Glucose to Continuous Glucose Monitoring in Combination with a mHealth App Improves Glycemic Control in People with Type 1 and Type 2 Diabetes	13
Prevalence, Cost, and Burden of Diabetic Ketoacidosis	13
Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study	13
Practical Application of Continuous Glucose Monitoring in Clinical Practice: Case Studies	13
Clinical Evaluation of a Novel CGM-Informed Bolus Calculator with Automatic Glucose Trend Adjustment	13
Twelve-Month Follow-up from a Randomized Controlled Trial of Simplified Meal Announcement Versus Precise Carbohydrate Counting in Adolescents with Type 1 Diabetes Using the MiniMed™ 780G Advanced Hybr	13
Predicting and Ranking Diabetic Ketoacidosis Risk among Youth with Type 1 Diabetes with a Clinic-to-Clinic Transferrable Machine Learning Model	13
Safety of Options to “Boost” (Enhancing Insulin Infusion Rates) and “Ease-Off” (Reducing Insulin Infusion Rates) in CamAPS FX Hybrid Closed-Loop System: A Real-World Analysis	13
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes	13
Immune Intervention and Replacement Therapies in Type 1 Diabetes	13
Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial	13
Use of Real-Time Continuous Glucose Monitoring Improves Glycemic Control and Other Clinical Outcomes in Type 2 Diabetes Patients Treated with Less Intensive Therapy	13
Changes in HbA1c Between 2011 and 2017 in Germany/Austria, Sweden, and the United States: A Lifespan Perspective	13
The Virtual DCCT: Adding Continuous Glucose Monitoring to a Landmark Clinical Trial for Prediction of Microvascular Complications	13
Exercising Safely with the MiniMed™ 780G Automated Insulin Delivery System	12
Decreasing the Burden of Carbohydrate Counting and Meal Announcement with Automated Insulin Delivery, Meal Recognition, and Autocorrection Doses: A Case Study	12
Performance of Subcutaneous Continuous Glucose Monitoring in Adult Critically Ill Patients Receiving Vasopressor Therapy	12
(Hybrid) Closed-Loop Systems: From Announced to Unannounced Exercise	12
Causes and Consequences of Continuous Glucose Monitor “Breaks”: Perspectives from Adolescents with Type 1 Diabetes	12
Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery	12
A Telehealth Program Using Continuous Glucose Monitoring and a Connected Insulin Pen Cap in Nursing Homes for Older Adults with Insulin-Treated Diabetes: The Trescasas Study	12
Continuous Glucose Monitoring (CGM) Readings During Patient-Reported Symptomatic Hypoglycemia: Assessment of the Advanced Technologies and Treatments for Diabetes Consensus Definition of CGM-Recorded	12
Using Digital Health Technology to Prevent and Treat Diabetes	12
MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience	11
Technologies in Diabetes—the Fourteenth ATTD Yearbook	11
Glucose Management Indicator for People with Type 1 Asian Diabetes Is Different from That of the Published Equation: Differences by Glycated Hemoglobin Distribution	11
Frequency and Detection of Insulin Infusion Site Failure in the Type 1 Diabetes Exchange Online Community	11
Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospectiv	11
Below Which Threshold of Glycemic Variability Is There a Minimal Risk of Hypoglycemia in People with Type 2 Diabetes?	11
With or Without Residual C-Peptide, Patients with Type 2 Diabetes Realize Glycemic Benefits from Real-Time Continuous Glucose Monitoring	11
Recent Improvements in Attainment of the Hemoglobin A1c Target of ≤7.0% Among Adults with Type 1 Diabetes in Ontario: A Retrospective Cohort Study	11
Correction to: Diabetes Technology & Therapeutics 2020; 22(5):395 − 403	11
Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia	10
Continuous and Intermittent Glucose Monitoring in 2021	10
Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience	10
Practical Diabetes Technology: Overcoming Barriers in the Real World	10
Which Treatment Modalities Are Being Used by Italian Children and Adolescents with Type 1 Diabetes?	10
Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial	10
Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes	10
Impact of COVID-19 on Health Economics and Technology of Diabetes Care: Use Cases of Real-Time Continuous Glucose Monitoring to Transform Health Care During a Global Pandemic	10
Comparison of Accuracy of Freestyle Libre Pro and Medtronic iPro2 Continuous Glucose Monitoring Systems in Pregnancy	10
Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems	10
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States	10
Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses	10
A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes	10
HbA1c and Glucose Management Indicator Discordance: A Real-World Analysis	10
Clinical Use of Continuous Glucose Monitoring in Critically Ill Pediatric Patients with Diabetic Ketoacidosis	10
Improved Effectiveness of Immediate Continuous Glucose Monitoring in Hypoglycemia-Prone People with Type 1 Diabetes Compared with Hypoglycemia-Focused Psychoeducation Following a Previous Structured E	10
Diabetes Technology and Therapy in the Pediatric Age Group	10
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Diabetes Technology & Therapeutics	9
Development of Machine Learning Models for the Identification of Elevated Ketone Bodies During Hyperglycemia in Patients with Type 1 Diabetes	9
Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes	9
The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference 27‐30 April 2022 I Barcelona & Online	9

Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6–17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial	9
New Insulins, Biosimilars, and Insulin Therapy	9
A Randomized Crossover Pilot Study Evaluating Glucose Control During Exercise Initiated 1 or 2 h After a Meal in Adults with Type 1 Diabetes Treated with an Automated Insulin Delivery System	9
Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass	9
New Insulins, Biosimilars, and Insulin Therapy	9
The Role of Retrospective Data Review in the Personal Use of Real-Time Continuous Glucose Monitoring: Perceived Impact on Quality of Life and Health Outcomes	9
Patterns of Continuous Glucose Monitor Use in Young Children Throughout the First 18 Months Following Type 1 Diabetes Diagnosis	9
Diabetes Technologies and the Human Factor	9
Diabetes Technology and Therapy in the Pediatric Age Group	9
Insulin Delivery Hardware: Pumps and Pens	9
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin	9
Possible Glycemic Effects of Vagus Nerve Stimulation Evaluated by Continuous Glucose Monitoring in People with Diabetes and Autonomic Neuropathy: A Randomized, Sham-Controlled Trial	8
Technology Utilization in Black Adolescents with Type 1 Diabetes: Exploring the Decision-Making Process	8
A Comparison of Glucose and Additional Signals for Three Different Exercise Types in Adolescents with Type 1 Diabetes Using a Hybrid Closed-Loop System	8
Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes	8
Real-Time Continuous Glucose Monitoring During the Coronavirus Disease 2019 Pandemic and Its Impact on Time in Range	8
Acknowledgment of Reviewers: 2024	8
Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion	8
Solutions to Address Inequity in Diabetes Technology Use in Type 1 Diabetes: Results from Multidisciplinary Stakeholder Co-creation Workshops	8
Incongruent Changes in Lab HbA1c and Average Glucose Underscore Significant Differences in Calibration Between Continuous Glucose Monitoring Systems During the Conduct of a Study on Glycemic Control i	8
Improved Estimation of Glycated Hemoglobin from Continuous Glucose Monitoring and Past Glycated Hemoglobin Data	8
Influence of Telemedicine on the Number of Visits and HbA1c Determinations in Latin American Children with Type 1 Diabetes	8
What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring	8
Diabetes Technology and the Human Factor	8
The Performance of Freestyle Libre Pro Flash Continuous Glucose Monitoring in Hospitalized Patients Treated with an Intravenous Insulin Infusion for Acute Prednisolone-Induced Hyperglycemia	8
Ranting in 2025: It’s Not the Same Rant	8
Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features	8
Impact of Hybrid Closed Loop Therapy on Hypoglycemia Awareness in Individuals with Type 1 Diabetes and Impaired Hypoglycemia Awareness	7
Intermittently Scanned Continuous Glucose Monitoring Data of Polish Patients from Real-Life Conditions: More Scanning and Better Glycemic Control Compared to Worldwide Data	7
The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes	7
Discordance Between Glucose Management Indicator and Glycated Hemoglobin in People Without Diabetes	7
Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multicenter, Single-Arm, Feasibility Trial	7
Perceptions of Diabetes Technology Use in Cystic Fibrosis-Related Diabetes Management	7
Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections	7
Clinical Outcomes with MiniMed^TM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes	7
Three Key Indices in Clinical Practice to Better Comprehend the Postprandial and Basal Glucose Contributions in Type 2 Diabetes	7
The Role of Sodium-Glucose Cotransporter Inhibitors with AID Systems in Diabetes Treatment: Is Continuous Ketone Monitoring the Solution?	7
Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study	7
Software Packages and Tools for the Analysis of Continuous Glucose Monitoring Data	7
A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes	7
Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System	7
Safety and Efficacy of an Adaptive Bolus Calculator for Type 1 Diabetes: A Randomized Controlled Crossover Study	7
Inaccurate Glucose Sensor Values After Hydroxyurea Administration	7
Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial	7
Diabetic Ketoacidosis at Diagnosis in Youth with Type 1 Diabetes Is Associated with a Higher Hemoglobin A1c Even with Intensive Insulin Management	7
Associations Between Hypoglycemia Awareness Status and Symptoms of Hypoglycemia Among Adults with Type 1 or Insulin-Treated Type 2 Diabetes Using the Hypo-METRICS Smartphone Application	7
Candidate Selection for Hybrid Closed Loop Systems	7
Association Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes	7
Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen	7
Development and Validation of a Machine Learning Model to Predict Weekly Risk of Hypoglycemia in Patients with Type 1 Diabetes Based on Continuous Glucose Monitoring	7
Assessment of a Decision Support System for Adults with Type 1 Diabetes on Multiple Daily Insulin Injections	7
Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark Study	7
Glycemic Variability and Disordered Eating Among Adolescents and Young Adults with Type 1 Diabetes: The Role of Disinhibited Eating	6
Partial Clinical Remission of Type 1 Diabetes in Swedish Children: A Longitudinal Study from the Swedish National Quality Register (SWEDIABKIDS) and the Better Diabetes Diagnosis (BDD) Study	6
Disparities in Continuous Glucose Monitoring Use Among Women of Reproductive Age with Type 1 Diabetes in the T1D Exchange	6
WITHDRAWN: Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial	6
Short-Term Diabetic Retinopathy Status in People with Type 1 Diabetes Commencing Automated Insulin Delivery	6
Outdated Assumptions Regarding Labeling of isCGM Sensor Performance and Requirement for Self-Monitored Blood Glucose Confirmation: Comment on Reddy and Oliver	6
The AH-HA! Project: Transforming Group Diabetes Self-Management Education Through the Addition of Flash Glucose Monitoring	6
Acknowledgment of Reviewers: 2023	6
ATTD 2021 Invited Speaker Abstracts	6
Seeing the Road Ahead—The Need to Address Accessibility of Diabetes Technology	6
A Minimized Measurement Scheme for Predicting HbA1c Using Discrete Self-Monitoring Blood Glucose Data Within 4 Weeks for People with Type 2 Diabetes	6
Enhancing Type 1 Diabetes Immunological Risk Prediction with Continuous Glucose Monitoring and Genetic Profiling	6
A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor	6
Temporary Target Versus Suspended Insulin Infusion in Patients with Type 1 Diabetes Using the MiniMed 780G Advanced Closed-Loop Hybrid System During Aerobic Exercise: A Randomized Crossover Clinical T	6
Once-Weekly Insulins	6
EValuating Glucose ContrOL Using a Next-GeneraTION Automated Insulin Delivery Algorithm in Patients with Type 1 and Type 2 Diabetes: The EVOLUTION Study	6
Ultrasound Detected Subcutaneous Changes in a Pediatric Cohort After Initiation of a New Insulin Pump or Glucose Sensor	6
Impact of an Advanced Hybrid Closed-Loop System on Glycemic Control Throughout the Menstrual Cycle in Women with Type 1 Diabetes Prone to Hypoglycemia	6
Exploratory Analysis of Glycemic Control and Variability Over Gestation among Pregnant Women with Type 1 Diabetes (T1D)	6
12-Month Efficacy of Advanced Hybrid Closed-Loop System in Adult Type 1 Diabetes Patients	6
ATTD 2022 Abstract Author Index	6
Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod^® 5 Automated Insulin Delivery System	6
Automated Insulin Delivery Around Exercise in Adults with Type 1 Diabetes: A Pilot Randomized Controlled Study	6
Beyond Glucose Monitoring: Multianalyte Sensor Use in Diabetes	6
A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G	6
Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Perinatal Complications	6
A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System	6
Relationship Between Moderate-to-Vigorous Physical Activity and Glycemia Among Young Adults with Type 1 Diabetes and Overweight or Obesity: Results from the Advancing Care for Type 1 Diabetes and Obes	6
A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes	6
Contrasting Glycemic Outcomes in Young People with Diabetic Ketoacidosis at Onset of Type 1 Diabetes	6
Effect of Arterialization on Venous Blood Glucose Concentrations and Implications for Observed Continuous Glucose Monitoring Accuracy	6
ONBOARD: A Feasibility Study of a Telehealth-Based Continuous Glucose Monitoring Adoption Intervention for Adults with Type 1 Diabetes	6
Composite Metric of Glycemic Control Q-Score Is Elevated in Pediatric and Adolescent/Young Adult Hematopoietic Stem Cell Transplant Recipients	6
Ranting in 2022: Not More of the Same	6
The Role of a “Technology Navigator” in an Academic Diabetes Clinic: A Feasibility Evaluation	6
Long-Term Improvements in Glycemic Control with Dexcom CGM Use in Adults with Noninsulin-Treated Type 2 Diabetes	6
Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Moni	5
Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy	5
Assessment of the Impact of Subcutaneous Catheter Change on Glucose Control in Patients with Type 1 Diabetes Treated by Insulin Pump in Open- and Closed-Loop Modes	5
New Insulins, Biosimilars, and Insulin Therapy	5
Immune Intervention in Type 1 Diabetes	5
Time in Range, Time in Tight Range, and Average Glucose Relationships Are Modulated by Glycemic Variability: Identification of a Glucose Distribution Model Connecting Glycemic Parameters Using Real-Wo	5
PIONEER PLUS: An Opportunity Knocking the Door for the Management of Diabesity	5